SG11202012473UA - Ophthalmic compositions and methods for the treatment of eye disorders - Google Patents
Ophthalmic compositions and methods for the treatment of eye disordersInfo
- Publication number
- SG11202012473UA SG11202012473UA SG11202012473UA SG11202012473UA SG11202012473UA SG 11202012473U A SG11202012473U A SG 11202012473UA SG 11202012473U A SG11202012473U A SG 11202012473UA SG 11202012473U A SG11202012473U A SG 11202012473UA SG 11202012473U A SG11202012473U A SG 11202012473UA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- methods
- ophthalmic compositions
- eye disorders
- disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/10—Quaternary compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
- C07D339/02—Five-membered rings
- C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201841024038 | 2018-06-27 | ||
IN201841024496 | 2018-07-01 | ||
IN201841028857 | 2018-07-31 | ||
PCT/IB2019/055086 WO2020003051A1 (en) | 2018-06-27 | 2019-06-18 | Ophthalmic compositions and methods for the treatment of eye disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202012473UA true SG11202012473UA (en) | 2021-01-28 |
Family
ID=68984462
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202012473UA SG11202012473UA (en) | 2018-06-27 | 2019-06-18 | Ophthalmic compositions and methods for the treatment of eye disorders |
Country Status (6)
Country | Link |
---|---|
US (1) | US20210277050A1 (en) |
EP (1) | EP3813794A4 (en) |
AU (1) | AU2019293958A1 (en) |
CA (1) | CA3104234A1 (en) |
SG (1) | SG11202012473UA (en) |
WO (1) | WO2020003051A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3228646A1 (en) * | 2021-08-18 | 2023-02-23 | Yandong Wang | Application of steroid compound in preparation of drug for preventing and/or treating eye floaters |
WO2023198192A1 (en) * | 2022-04-15 | 2023-10-19 | 广州润尔眼科生物科技有限公司 | Use of steroid compound in preparing drugs for preventing and/or treating presbyopia |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2993196A1 (en) * | 2015-07-27 | 2017-02-02 | Catacore, Inc | Compositions for the treatment of cataracts |
AU2016321254A1 (en) * | 2015-09-08 | 2018-04-05 | Viewpoint Therapeutics, Inc. | Compounds and formulations for treating ophthalmic diseases |
US20200281944A1 (en) * | 2017-11-17 | 2020-09-10 | Mahmood Piraee | Combinations Of Lanosterol Or 25-Hydroxycholesterol Including Derivatives Thereof Useful In The Treatment Of Lens Disorders |
-
2019
- 2019-06-18 SG SG11202012473UA patent/SG11202012473UA/en unknown
- 2019-06-18 CA CA3104234A patent/CA3104234A1/en active Pending
- 2019-06-18 WO PCT/IB2019/055086 patent/WO2020003051A1/en active Search and Examination
- 2019-06-18 EP EP19826974.8A patent/EP3813794A4/en active Pending
- 2019-06-18 US US17/250,281 patent/US20210277050A1/en active Pending
- 2019-06-18 AU AU2019293958A patent/AU2019293958A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2019293958A1 (en) | 2021-02-04 |
US20210277050A1 (en) | 2021-09-09 |
EP3813794A1 (en) | 2021-05-05 |
EP3813794A4 (en) | 2022-07-13 |
CA3104234A1 (en) | 2020-01-02 |
WO2020003051A1 (en) | 2020-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202002066B (en) | Compositions and methods for the treatment of eye disorders | |
EP3463315C0 (en) | Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization | |
IL282624A (en) | Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders | |
IL287280A (en) | Compounds and methods for the treatment of ocular disorders | |
SG11202103033WA (en) | Compositions and methods for the treatment of presbyopia | |
IL287264A (en) | Compounds and methods for the treatment of ocular disorders | |
IL275985A (en) | Compositions and methods for treating retinal disorders | |
IL273531A (en) | Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases | |
ZA202002991B (en) | Methods and compositions for assessing and treating intraocular diseases and disorders | |
EP3713553A4 (en) | Compositions and methods for treatment of eye diseases | |
ZA202002075B (en) | Compounds, compositions and methods for treatment of eye disorders and skin diseases | |
IL269400A (en) | Drugs and compositions for the treatment of ocular disorders | |
IL287594A (en) | Compositions and methods for the treatment of retinal degeneration | |
SG11202012473UA (en) | Ophthalmic compositions and methods for the treatment of eye disorders | |
EP3697354A4 (en) | Compositions and methods for treating eye disorders | |
IL282898A (en) | Ophthalmic compositions and methods for the treatment of skin diseases and eye diseases | |
EP3658217A4 (en) | Treatment of eye disorders | |
IL280588A (en) | Ophthalmic compositions and methods for the treatment of eye disorders and skin diseases | |
EP4069220A4 (en) | Ophthalmic formulations for the treatment of presbyopia | |
EP3658218A4 (en) | Treatment of eye disorders | |
AU2017902346A0 (en) | Methods of treating ocular disorders | |
AU2017904032A0 (en) | Implants for the Treatment of Diseases and Disorders | |
IT201700099156A1 (en) | Nanoparticle ophthalmic composition for the treatment of eye disorders or diseases | |
EP3129054A4 (en) | Methods and compositions for the treatment of ocular diseases and disorders |